Forte Biosciences, Inc.
NASDAQ:FBRX · NASDAQ Capital Market
+$0.30 today
Vol 0.17M · Avg 0.30M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$69.4M -95.5% | -$35.5M -12.7% | -$31.5M -126.8% | -$13.9M +36.1% | -$21.7M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $64.0K +64.1% | $39.0K +333.3% | $9.0K | $0 -100.0% | $36.0K | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $1.0M | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $6.3M +102.2% | $3.1M -5.8% | $3.3M -18.2% | $4.0M -4.7% | $4.2M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | $11.4M +547.2% | $1.8M +548.2% | -$392.0K -123.3% | $1.7M +133.2% | $720.0K | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $0 | $0 | $0 | $0 | $0 | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $5.5M +83.5% | $3.0M +1014.8% | $271.0K +30.9% | $207.0K +170.4% | -$294.0K | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $5.8M +561.1% | -$1.3M -90.6% | -$663.0K -145.0% | $1.5M +45.2% | $1.0M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | -$237.0K -50.0% | -$158.0K -20.6% | -$131.0K | $0 -100.0% | $61.0K | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$50.9M -65.5% | -$30.7M -7.1% | -$28.7M -250.7% | -$8.2M +50.9% | -$16.7M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$116.0K -213.5% | -$37.0K +58.0% | -$88.0K | $0 | $0 | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 +100.0% | -$36.0M -260.8% | -$10.0M | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $36.4M | $0 -100.0% | $10.1M | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $36.2M +200.7% | -$36.0M -76680.9% | $47.0K | $0 | $0 | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 | $0 | $0 | $0 | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $76.8M +45.0% | $53.0M +114.2% | $24.7M +242.3% | $7.2M +11559.7% | $62.0K | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 +100.0% | -$1.0K | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$7.5M -554.1% | -$1.1M -2495.5% | -$44.0K -466.7% | $12.0K +111.3% | -$106.0K | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $69.4M +33.8% | $51.9M +110.1% | $24.7M +240.9% | $7.2M +16556.8% | -$44.0K | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $54.7M +467.7% | -$14.9M -274.4% | -$4.0M -321.1% | -$944.0K +94.4% | -$16.7M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$51.0M -65.7% | -$30.8M -6.9% | -$28.8M -251.8% | -$8.2M +50.9% | -$16.7M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Fate Therapeutics, Inc.
NASDAQ:FATE
$228.46M
Nkarta, Inc.
NASDAQ:NKTX
$195.68M
Alector, Inc.
NASDAQ:ALEC
$181.53M
Molecular Partners AG
NASDAQ:MOLN
$147.42M
PepGen Inc.
NASDAQ:PEPG
$123.81M
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
$101.88M
Cardiff Oncology, Inc.
NASDAQ:CRDF
$82.73M
Elicio Therapeutics, Inc.
NASDAQ:ELTX
$72.15M
Actuate Therapeutics Inc
NASDAQ:ACTU
$51.20M
Applied Therapeutics, Inc.
APLT
$14.86M
SEC Filings
Recent regulatory filings
No filings found.
Does FBRX generate free cash flow?
Forte Biosciences, Inc. (FBRX) generated -$50,998,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does FBRX produce?
Operating cash flow was -$50,882,000.00, before capital expenditures of $116,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.